IS SMALL BEAUTIFUL? CHALLENGES FACING IRELAND IN ADOPTING THE FOURTH HURDLE

CLINICAL OUTCOMES STUDY METHODOLOGY

W1: OUTCOMES RESEARCH- ITS ROLE IN RISK MANAGEMENT
DISCUSSION LEADERS: John Parkinson, PhD, Head, GPRD, MHRA, London, UK; Tjeerd P Van Staa, MD, PhD, Head of Research, GPRD, London, UK; Frank De Vries, PhD, Lecturer, Utrecht University, Institute for Pharmaceutical Science, Utrecht, Holland, The Netherlands.

W2: RISK FACTORS THAT CHANGE OVER TIME: HOW TO ESTIMATE THEIR IMPACT ON THE OCCURRENCE OF HEALTH OUTCOMES?
DISCUSSION LEADERS: K Jack Ishak, PhD, Director, Biostatistics, Caro Research Institute, Montreal, QC, Canada; Krista F. Huybrechts, MS, Senior Researcher, Caro Research Institute, Concord, MA, USA; J. Jaime Caro, MDCM, FRCPC, FAC, President & Scientific Director, Caro Research Institute, Concord, MA, USA.

COST STUDY METHODOLOGY

W3: THE USE OF EPISODES OF CARE TO DEFINE AND MEASURE UNITS OF HEALTH CARE COSTS
DISCUSSION LEADERS: William Crown, PhD, President, i3 Innovus, Waltham, MA, USA; Steven Wickstrom, MS, Senior Director of Research and Development, Ingenix, Eden Prairie, MN, USA.

HEALTH CARE POLICY AND FORMULARY DEVELOPMENT USING OUTCOMES RESEARCH

W4: CONDITIONAL REIMBURSEMENT FOR HOSPITAL BASED DRUGS IN THE NETHERLANDS: POLICY MEASURE, COST-EFFECTIVENESS CRITERIUM, FUTURE OUTCOMES RESEARCH, METHODOLOGICAL AND CLINICAL CHALLENGES
DISCUSSION LEADERS: Gepke Delwel, PhD, Policy Advisor, CVZ Healthcare Insurance Board, Diemen, The Netherlands; Johan L Severens, PhD, Professor of Health Technology Assessment, Academic Hospital Maastricht, Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht, The Netherlands; Carin A Uyl-de Groot, PhD, Professor, iMTA/VUMC, Rotterdam, The Netherlands.

W5: VALUE AND COST-EFFECTIVENESS: US AND EUROPEAN PERSPECTIVES
DISCUSSION LEADERS: Sean D. Sullivan, PhD, Professor, University of Washington, Department of Pharmacy, Seattle, WA, USA; Brian W. Bresnahan, PhD, Senior Fellow, University of Washington, Department of Pharmacy, PORPP, Seattle, WA, USA; Peter J. Neumann, ScD, Professor, Tufts-New England Medical Center, Institute for Clinical Research and Health Policy Studies, Boston, MA, USA; Louis P. Garrison, PhD, Professor of Pharmacy, University of Washington, Department of Pharmacy, Seattle, WA, USA.

PATIENT-REPORTED OUTCOMES STUDY METHODOLOGY (INCLUDING PREFERENCE-BASED & COMPLIANCE STUDIES)

W6: INTERVENTIONS THAT ENHANCE MEDICATION COMPLIANCE AND PERSISTENCE: THEORETICAL GROUNDING, AND ECONOMIC ASSESSMENT
DISCUSSION LEADERS: Dyfrig Hughes, PhD, Senior Research Fellow, University of Wales, Bangor, Centre for Economics and Policy in Health, Bangor, UK; Femida Gwadry Sridhar, PhD, RPH, MSc, Assistant Professor, University of Western Ontario & McMaster University, ON, Canada; Rachel Elliott, PhD, Professor, University of Nottingham, Division of Social Research in Medicines and Health School of Pharmacy, Nottingham, UK; Warren Cowell, MSc, Health Economist, Roche Products Ltd, Healthcare Management, Welwyn Garden City, UK; Sangeeta Budhia, PhD, Consultant, Heron Evidence Development, Letchworth Garden City, Hertfordshire, UK.

W7: COMPLIANCE, ADHERENCE, AND PERSISTENCE IN HEALTH OUTCOMES RESEARCH: WHY, WHEN, AND WHAT'S THE RIGHT CHOICE
DISCUSSION LEADERS: B Tang, MD, PhD, Associate Director, Centocor, Inc, Horsham, PA, USA; M I Rahman, MD, MPH, Senior Director of Pharmacoepidemiology, Centocor, Inc, Horsham, PA, USA

CLINICAL OUTCOMES STUDY METHODOLOGY

W8: USE OF ELECTRONIC MEDICAL RECORD (EMR) DATA IN OUTCOMES RESEARCH
DISCUSSION LEADERS: Gary M Oderda, PharmD, MPH, Professor, University of Utah, College of Pharmacy, Department of Pharmacotherapy, Salt Lake City, UT, USA; Michael Lieberman, MD, MS, Informatics Director, GE Medical Systems, Hillsboro, OR, USA; Carl V. Asche, PhD, Research Associate Professor, University of Utah, College of Pharmacy, Outcomes Research Center, Department of Pharmacotherapy, Salt Lake City, UT, USA; Diana Brixner, RPh, PhD, Associate Professor and Chair, Department of Pharmacotherapy, Executive Director Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, UT, USA

COST STUDY METHODOLOGY

W9: THROUGH A GLASS DARKLY: TRANSPARENCY IN DECISION-ANALYTIC MODELS
DISCUSSION LEADERS: Nancy Neil, PhD, Senior Director, Health Economics, ICON Clinical Research, Lifecycle Sciences Group, San Francisco, CA, USA; Michael Chambers, MA, MSc, Director of Health Economics, GlaxoSmithKline, Global Health Outcomes, Uxbridge, Middlesex, UK.

W10: ADHERENCE TO CLINICAL GUIDELINES: A KEY CONCEPT IN CLINICAL AND ECONOMIC MODELS FOR DIAGNOSTIC DEVICES
DISCUSSION LEADERS: Won Chan Lee, PhD, Director, Abt Associates Inc, Health Economic Research and Quality of Life Evaluation Services, Bethesda, MD, USA; Yu-Chen Yeh, MS, Lead Pharmacoeconomist, Abt Associates Inc, Health Economic Research & Quality of Life Evaluation Services, Lexington, MA, USA; Mary Jo Williams, BS, Principal, Health Economics, Medtronic, Gastroenterology and Urology, Shoreview, MN, USA.

HEALTH CARE POLICY AND FORMULARY DEVELOPMENT USING OUTCOMES RESEARCH

W11: FACTORS TO CONSIDER IN SELECTING A STUDY DESIGN FOR POST-LAUNCH RESEARCH – STRATEGIC, METHODOLOGIC AND PRACTICAL CONSIDERATIONS
DISCUSSION LEADERS: Deborah Marshall, PhD, Vice President, Global Health Economics and Outcomes, i3 Innovus, Burlington, ON, Canada; Monique Martin, MBA, Health Economist, i3 Innovus, Health Outcomes, Uxbridge, Middlesex, UK; Mike F Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK.

W12: THE IMPLICATIONS OF VALUE BASED PRICING FOR THE PRICING AND REIMBURSEMENT OF PHARMACEUTICALS.
DISCUSSION LEADERS: Keith Tolley, MPhil, Research Director, Mapi Values, Market Access Unit, Bollington, Cheshire, UK; Francis Pang, MSc, Phil, DM, European Health Economics Manager, Takeda Pharmaceutical Company Limited, Global Research and Development Centre (Europe), London, UK; Ulrich Oron, MSc, RPh, MBA, Associate Director Market Access, Mapi Values Netherlands, Houten, The Netherlands.

PATIENT-REPORTED OUTCOMES STUDY METHODOLOGY (INCLUDING PREFERENCE-BASED & COMPLIANCE STUDIES)

W13: SPECIFYING THE CONCEPTUAL FRAMEWORK OF AN INSTRUMENT: TWO TOOLS TO MAKE YOUR LIFE EASIER
DISCUSSION LEADERS: Pennifer Erickson, PhD, Co-founder, OLGA, State College, PA, USA; Richard J Willke, PhD, Senior Director/Group Leader, Pfizer Inc, Worldwide Outcomes Research, Bridgewater, NJ, USA.

W14: FROM MINIMAL IMPORTANT DIFFERENCE TO CUMULATIVE RESPONSE CURVES: KEYS TO THE INTERPRETATION OF PRO RESULTS
DISCUSSION LEADERS: Benoit Arnould, MSc, MA, Director, Patient Scales for Clinical Practice, Mapi Values France, Patient Scales for Clinical Practice, Lyon, France; Muriel Viala, MSc, Senior Research Analyst, Mapi Values France, Lyon, France; Gilles Berdeaux, MD, Associate Director, Alcon France, Rueil-Malmaison, France; Aude Roborel de Climens, PhD, Research Associate, Mapi Values France, Lyon, France.